ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer.  The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing.  ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.

Biotechnology

Health Care

Pharmaceutical

Therapeutics

Oric Pharmaceuticals

Jacob Chacko

Chester Chae

Kevin Sun

Jian Wang

Sandy Koppenol

Dan Iazzetti

Pratik Multani

Christian V. Kuhlen

Matt Panuwat

Edna Chow Maneval

Dominic Piscitelli

Lori Friedman

The Research and Development team at Oric Pharmaceuticals is responsible for discovering and developing innovative oncology treatments targeting mechanisms of resistance. They work on advancing the company's pipeline, including the lead asset ORIC-101, by conducting preclinical and clinical research, managing regulatory affairs, developing formulations and drug delivery systems, and utilizing data science and bioinformatics to support their findings.

Research and Development

Scientific Research Team

Board and Advisory Team

Research and Development

About

Team members

Other teams at Oric Pharmaceuticals

Scientific Research Team

Board and Advisory Team